These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38104105)
1. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study. Zheng X; Zhang L; Wu L; Zhao J; Sun J; Fang Y; Zhou J; Chu Q; Shen Y; Yang Z; Chen L; Huang M; Lin X; Liu Z; Shen P; Wang Z; Wang X; Wang H; Han Z; Liu A; Zhang H; Ye F; Gao W; Wu F; Song Z; Chen S; Zhou C; Wang Q; Xu C; Huang D; Zheng X; Miao Q; Jiang K; Xu Y; Wu S; Wang H; Zhang Q; Yang S; Li Y; Chen S; Lin G BMC Cancer; 2023 Dec; 23(1):1244. PubMed ID: 38104105 [TBL] [Abstract][Full Text] [Related]
2. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682 [TBL] [Abstract][Full Text] [Related]
3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of immune checkpoint inhibitors in advanced Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y Front Immunol; 2022; 13():975246. PubMed ID: 36159795 [TBL] [Abstract][Full Text] [Related]
5. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. Naqash AR; McCallen JD; Mi E; Iivanainen S; Marie MA; Gramenitskaya D; Clark J; Koivunen JP; Macherla S; Jonnalagadda S; Polsani S; Jiwani RA; Hafiz M; Muzaffar M; Brunetti L; Stroud CRG; Walker PR; Wang K; Chung Y; Ruppin E; Lee SH; Yang LV; Pinato DJ; Lee JS; Cortellini A J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852738 [TBL] [Abstract][Full Text] [Related]
6. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116 [TBL] [Abstract][Full Text] [Related]
7. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study. Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645 [TBL] [Abstract][Full Text] [Related]
9. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372 [TBL] [Abstract][Full Text] [Related]
10. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data. Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Zhou S; Ren F; Meng X Front Immunol; 2022; 13():955944. PubMed ID: 36238280 [TBL] [Abstract][Full Text] [Related]
12. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593 [TBL] [Abstract][Full Text] [Related]
13. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J Front Immunol; 2020; 11():1173. PubMed ID: 32587591 [No Abstract] [Full Text] [Related]
14. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. Zhang J; Pan Y; Shi Q; Zhang G; Jiang L; Dong X; Gu K; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Bai J; Xie W; Zhao W; Wu L; Zhou C Cancer Commun (Lond); 2022 Jan; 42(1):3-16. PubMed ID: 34699693 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Rousseau A; Tagliamento M; Auclin E; Aldea M; Frelaut M; Levy A; Benitez JC; Naltet C; Lavaud P; Botticella A; Grecea M; Chaput N; Barlesi F; Planchard D; Besse B Eur J Cancer; 2023 Mar; 182():107-114. PubMed ID: 36758475 [TBL] [Abstract][Full Text] [Related]
17. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
18. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T Front Immunol; 2022; 13():827788. PubMed ID: 35211122 [TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170 [TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q Front Immunol; 2022; 13():1059995. PubMed ID: 36569915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]